Open this publication in new window or tab >>Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Research, Akershus University Hospital, Norway.
Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia; Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
Umeå University, Faculty of Medicine, Department of Nursing. Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden.
Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Department of Neurology, Akershus University Hospital, Norway.
Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands.
Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands; Department of Psychiatry, Maastricht University, Maastricht, Netherlands.
Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden; Karolinska University Hospital, Stockholm, Sweden.
Department of Neurology, Akershus University Hospital, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Show others...
2025 (English)In: Journal of Alzheimer's Disease, ISSN 1387-2877, E-ISSN 1875-8908, Vol. 104, no 4, p. 1167-1184Article in journal (Refereed) Published
Abstract [en]
Background The introduction of anti-amyloid treatments (AAT) for Alzheimer's disease (AD) has put the cost-effectiveness into focus.
Objective Estimate the potential cost-effectiveness of diagnostic pathways combined with AAT for early AD.
Methods Diagnostic accuracy of blood-based (BBM) and cerebrospinal fluid (CSF) biomarkers was obtained from Norwegian memory clinics using positron emission tomography (PET) as reference standard. In a health-economic model, the cost-effectiveness of three diagnostic strategies was estimated relying either on BBM (p-tau 217), CSF (Aβ42/40 ratio), and BBM with CSF confirmatory testing and compared with standard of care (SoC) and compared with CSF-AAT. The model consisted of a decision tree reflecting the diagnostic process and a subsequent Markov cohort model starting at mild cognitive impairment due to AD. All strategies except SoC were combined with AAT including costs of treatment (assumed €5000/year), infusions and monitoring.
Results Compared with SoC all three strategies (CSF-AAT, BBM-AAT, and BBM-CSF-AAT) resulted in QALY gains at higher costs, with an incremental cost-effectiveness ratio (ICER) of 110k€, 141k€ and 110k€ respectively. Compared with CSF-AAT both BBM-AAT and BBM-CSF-AAT strategies resulted in QALYs lost at lower costs, with an ICER of 27k€ and 109k€ respectively. Results were particularly sensitive to the price of AAT and possible subcutaneous administration.
Conclusions Compared with SoC all three strategies are potentially not cost-effective as they exceeded the Swedish maximum willingness to pay threshold of €94,800 per QALY gained. BBM-CSF-AAT versus CSF-AAT is potentially cost-effective if willing to accept its QALY loss. Discussions on budget impact on different payers are needed after introducing AAT.
Place, publisher, year, edition, pages
Sage Publications, 2025
Keywords
Alzheimer's disease, anti-amyloid treatment, biomarkers, blood-based biomarkers, cost-effectiveness, disease modifying treatment, donanemab, lecanemab
National Category
Rheumatology Autoimmunity and Inflammation Geriatrics
Identifiers
urn:nbn:se:umu:diva-238613 (URN)10.1177/13872877251323231 (DOI)001459092400001 ()40111937 (PubMedID)2-s2.0-105003787855 (Scopus ID)
Funder
The Research Council of Norway, JPND2019-466-236/NRC 311993
2025-05-132025-05-132025-05-13Bibliographically approved